AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

ENDRA Life Sciences Inc.

$5.67 +$1.38 (+32.28%)
NASDAQ · 14 Sep 2026 18:15 UTC
Previous Close
$5.62
Day Range
$5.5$5.83
Year Range
$2.96$9.85
Market Cap
7.21M
AVG Volume
33.28K
Trailing/Forward PE
-0.9/-
PEG ratio
0.06
Dividend Yield
-
Next Earnings Date
2026-11-13
Primary Exchange
NASDAQUS
Revenue (USD)
0200K400K600K2016201720182019202020212022202320242025
NDRA Revenue (USD) by year
PeriodRevenue (USD)
20250
20240
20230
20220
20210
20200
20190
20186.17K
2017351.62K
2016515.58K
Net Income (USD)
-15M-10M-5M02016201720182019202020212022202320242025
NDRA Net Income (USD) by year
PeriodNet Income (USD)
2025-7.03M
2024-11.51M
2023-10.06M
2022-13.18M
2021-11.23M
2020-11.73M
2019-13.31M
2018-9.8M
2017-5.38M
2016-2.77M
Operating Income (USD)
-15M-10M-5M02016201720182019202020212022202320242025
NDRA Operating Income (USD) by year
PeriodOperating Income (USD)
2025-5.76M
2024-10.82M
2023-10.52M
2022-13.16M
2021-11.5M
2020-11.5M
2019-10.84M
2018-9.02M
2017-4.63M
2016-1.79M
EBITDA (USD)
-1T01T2T3T2016201720182019202020212022202320242025
NDRA EBITDA (USD) by year
PeriodEBITDA (USD)
2025-6.87M
2024-3.98M
2023-9.78M
20222.86T
2021-11.31M
2020-11.33M
2019-10.84M
2018-8.98M
2017-4.56M
2016-1.72M
Cash Flows (USD)
-15M-10M-5M02016201720182019202020212022202320242025
NDRA Cash Flows (USD) by year
PeriodCash Flows (USD)
2025-8.2M
2024-7.42M
2023-9.58M
2022-12.97M
2021-11.17M
2020-10.85M
2019-8.63M
2018-7.9M
2017-3.31M
2016-1.32M
EPS (USD)
-1500000-1000000-50000002016201720182019202020212022202320242025
NDRA EPS (USD) by year
PeriodEPS (USD)
2025-8.93
2024-12.77
2023-5.7
2022-1327727.47
2021-5.49
2020-14.31
2019-31.25
2018-44.24
2017-27.53
2016-14.21
Expenses (USD)
05M10M15MR&DSG&ACapex2016201720182019202020212022202320242025
NDRA Expenses (USD) by year
PeriodExpenses (USD)
20258.78M
202410.83M
202310.55M
202213.36M
202111.54M
202011.6M
201910.89M
20188.94M
20174.81M
20162.07M
Cash & Debt (USD)
02.5M5M7.5M10MCashLong Term DebtShort Term Debt2016201720182019202020212022202320242025
NDRA Cash & Debt (USD) by year
PeriodCash & Debt (USD)
2025762.37K
20243.23M
20232.83M
20224.89M
20219.46M
20207.23M
20196.17M
20186.47M
20175.6M
2016144.95K
Debt ratios
-0.100.10.20.30.420182019202020212022202320242025
NDRA Debt ratios by year
PeriodDebt ratios
2025-0
2024-0
2023-0
2022-0
20210.2
20200.18
20190.21
20180.39
Margins
0%25%50%75%100%2015201620172018
NDRA Margins by year
PeriodMargins
2018100%
201750.86%
201654.25%
201567.46%
Return on Capital
-600%-400%-200%0%200%400%2016201720182019202020212022202320242025
NDRA Return on Capital by year
PeriodReturn on Capital
2025-310.93%
2024-449.46%
2023-177.77%
2022-182.93%
2021-104.14%
2020-163.55%
2019-279.5%
2018-156.79%
2017-101.92%
2016310.3%
Shares Outstanding
01M2M3M2016201720182019202020212022202320242025
NDRA Shares Outstanding by year
PeriodShares Outstanding
2025787.02K
2024536.91K
20231.71M
20221.93M
20212.1M
20201.19M
2019575.44K
2018371.13K
2017195.35K
2016195.35K
Book Value Per Share (USD)
-1001020302016201720182019202020212022202320242025
NDRA Book Value Per Share (USD) by year
PeriodBook Value Per Share (USD)
20252.87
20244.77
20233.31
20223.73
20215.15
20206
20198.27
201816.84
201727.01
2016-4.58
Total Assets (USD)
05M10M15M2016201720182019202020212022202320242025
NDRA Total Assets (USD) by year
PeriodTotal Assets (USD)
20253.85M
20244.45M
20236.75M
20229.27M
202112.87M
20208.76M
20197.18M
20187.22M
20176.12M
2016490.76K
Employee Count
0102030201720182019202020212022202320242025
NDRA Employee Count by year
PeriodEmployee Count
20259
202421
202321
202221
202122
202018
201915
201811
201713
Free Cash Flow Yield
-500%-400%-300%-200%-100%0%med -152.4%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
NDRA Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Sep 26-105.38%
Sep 26-97.89%
Aug 26-118.21%
Aug 26-131.9%
Aug 26-132.49%
Aug 26-145.14%
Jul 26-142.05%
Jul 26-137.38%
Jul 26-133.8%
Jul 26-119.01%
Jul 26-141.45%
Jun 26-133.8%
Jun 26-140.26%
Jun 26-146.42%
Jun 26-157.84%
May 26-121.39%
May 26-122.28%
May 26-132.21%
May 26-210.48%
May 26-210.48%
Apr 26-209.63%
Apr 26-162.79%
Apr 26-210.91%
Apr 26-222.15%
Mar 26-154.13%
Mar 26-194.34%
Mar 26-193.22%
Mar 26-199.55%
Feb 26-161.56%
Feb 26-169.74%
Feb 26-191.02%
Feb 26-172.36%
Jan 26-176.44%
Jan 26-150.67%
Jan 26-140.27%
Jan 26-144.19%
Jan 26-156.29%
Dec 25-131.98%
Dec 25-129.94%
Dec 25-121.91%
Dec 25-112.5%
Nov 25-113.45%
Nov 25-155.93%
Nov 25-100.07%
Nov 25-149.24%
Oct 25-148.67%
Oct 25-156.1%
Oct 25-127.33%
Oct 25-120.45%
Oct 25-135.74%
Sep 25-148.95%
Sep 25-162.94%
Sep 25-164.66%
Sep 25-182.79%
Aug 25-190.83%
Aug 25-177.79%
Aug 25-160.6%
Aug 25-270.9%
Aug 25-242.92%
Jul 25-178.14%
Jul 25-165.13%
Jul 25-145.15%
Jul 25-332.13%
Jun 25-328.42%
Jun 25-368.57%
Jun 25-340.79%
Jun 25-349.92%
May 25-350.96%
May 25-378.05%
May 25-364%
May 25-423.73%
May 25-224.61%
Apr 25-347.07%
Apr 25-376.39%
Apr 25-375.37%
Apr 25-203.41%
Mar 25-177.79%
Mar 25-167.46%
Mar 25-175.63%
Mar 25-205.15%
Feb 25-166.3%
Feb 25-166.3%
Feb 25-143.73%
Feb 25-136.9%
Jan 25-149.7%
Jan 25-127.9%
Jan 25-119.81%
Jan 25-120.41%
Jan 25-107.96%
Dec 24-114.3%
Dec 24-130.68%
Dec 24-168.63%
Dec 24-136.12%
Nov 24-126.11%
Nov 24-141.47%
Nov 24-116.37%
Nov 24-87.18%
Nov 24-54.08%
Oct 24-53.91%
Oct 24-74.21%
Price to Sales
02000000400000060000008000000med 48466.63Sep 17Jan 18Apr 18Jul 18Oct 18Feb 19May 19
NDRA Price to Sales by year
PeriodPrice to Sales
May 192987570.52
May 193240041.27
Apr 193219002.04
Apr 193218791.65
Apr 193197962.81
Apr 193303158.96
Mar 193492512.02
Mar 196753592.52
Mar 194923179.59
Mar 191018623.3
Mar 19897232.95
Feb 19944733.52
Feb 191002789.77
Feb 19986956.25
Feb 191076679.55
Jan 19976400.57
Jan 19981678.41
Jan 191134735.8
Jan 19965844.89
Dec 18939455.68
Dec 18881399.43
Dec 181129457.95
Dec 181166402.84
Nov 181746965.34
Nov 182095302.84
Nov 182206137.5
Nov 182359194.89
Nov 18110522.25
Oct 18116700.51
Oct 1894733.35
Oct 1855833.18
Oct 1865443.81
Sep 1870020.31
Sep 1875740.92
Sep 1871393.25
Sep 1859045.88
Aug 1859723.2
Aug 1859036.73
Aug 1861675.07
Aug 1844515.48
Aug 1846626.13
Jul 1844131.73
Jul 1840065.85
Jul 1842500.77
Jul 1850079.92
Jun 1848928.65
Jun 1850847.42
Jun 1842212.96
Jun 1833386.61
Jun 1836788.59
May 1836170.75
May 1838250.69
May 1847642.16
May 1853279.26
Apr 1848223.57
Apr 1848709.69
Apr 1849973.61
Apr 1845627.66
Mar 1850556.96
Mar 1856001.56
Mar 1822887.53
Mar 1824318
Mar 1823563.03
Feb 1825430.59
Feb 1826932.59
Feb 1826940.53
Feb 1828529.95
Jan 1823364.36
Jan 1821536.53
Jan 1828847.83
Jan 1832185.59
Dec 1738625.1
Dec 1730198.83
Dec 1732662.42
Dec 1729483.59
Dec 1728529.95
Nov 1729801.48
Nov 1718755.06
Nov 1727427.65
Nov 1726235.15
Oct 1731005.17
Oct 1734582.69
Oct 1736967.71
Oct 1739483.9
Sep 1737921.71
Sep 1738601.44
Sep 1736967.71
Sep 1738303.32
Sep 1738756.47
Aug 1738875.72
Aug 1738637.22
Aug 1739352.72
Aug 1745221.02
Jul 1745088.4
Jul 1746281.92
Jul 1750392.92
Jul 1747608.05
Jun 1751719.05
EV/EBITDA
0000.010.010.01med 0.01Jun 22Aug 22Sep 22Nov 22Jan 23Mar 23May 23
NDRA EV/EBITDA by year
PeriodEV/EBITDA
May 230
May 230
Apr 230
Apr 230
Apr 230
Apr 230
Mar 230
Mar 230
Mar 230
Mar 230
Mar 230
Feb 230
Feb 230
Feb 230
Feb 230
Jan 230
Jan 230.01
Jan 230.01
Jan 230.01
Dec 220
Dec 220.01
Dec 220.01
Dec 220
Dec 220
Nov 220
Nov 220
Nov 220.01
Nov 220.01
Oct 220.01
Oct 220.01
Oct 220.01
Oct 220.01
Sep 220.01
Sep 220.01
Sep 220.01
Sep 220.01
Sep 220.01
Aug 220.01
Aug 220.01
Aug 220.01
Aug 220.01
Jul 220.01
Jul 220.01
Jul 220.01
Jul 220.01
Jul 220.01
Jun 220.01
Jun 220.01
Jun 220.01
Jun 220.01
May 220.01
May 220.01
May 220.01
Price to Book
0102030med 1.93Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
NDRA Price to Book by year
PeriodPrice to Book
Sep 261.18
Sep 261.27
Aug 261.05
Aug 260.94
Aug 260.94
Aug 263.09
Jul 263.16
Jul 263.26
Jul 263.35
Jul 263.77
Jul 263.17
Jun 263.35
Jun 263.2
Jun 263.06
Jun 262.84
May 263.69
May 263.67
May 263.39
May 261.72
May 261.72
Apr 261.73
Apr 262.23
Apr 261.72
Apr 261.63
Mar 2619.32
Mar 2615.32
Mar 2615.41
Mar 2614.92
Feb 2618.43
Feb 2617.54
Feb 2615.59
Feb 2617.28
Jan 2616.88
Jan 2619.77
Jan 2621.23
Jan 2620.65
Jan 2619.05
Dec 2522.56
Dec 2522.92
Dec 2524.43
Dec 2526.47
Nov 2526.25
Nov 2519.1
Nov 2529.76
Nov 252.55
Oct 252.56
Oct 252.43
Oct 252.98
Oct 253.15
Oct 252.8
Sep 252.55
Sep 252.33
Sep 252.31
Sep 252.08
Aug 251.99
Aug 252.14
Aug 252.37
Aug 251.38
Aug 251.54
Jul 252.1
Jul 252.26
Jul 252.58
Jul 251.13
Jun 251.14
Jun 251.01
Jun 251.1
Jun 251.07
May 251.07
May 250.99
May 251.03
May 250.68
May 251.29
Apr 250.83
Apr 250.77
Apr 250.77
Apr 250.6
Mar 250.69
Mar 250.73
Mar 250.7
Mar 250.6
Feb 250.74
Feb 250.74
Feb 250.85
Feb 250.89
Jan 250.82
Jan 250.96
Jan 251.02
Jan 251.02
Jan 251.13
Dec 241.07
Dec 240.94
Dec 240.73
Dec 240.9
Nov 240.97
Nov 240.87
Nov 240.86
Nov 241.15
Nov 241.86
Oct 241.86
Oct 241.35
ENDRA Life Sciences Inc.
NDRA
Stockpicker

Video analysis: NDRA

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: NDRA

ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

businesswire.com · 17 Aug 2026

ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), reported financial results for the quarter ended June 30, 2026, and provided a business update. Second Quarter 2026 and Recent Highlights On June 25, 2026, ENDRA entered into a definitive merger agreement with ASP Isotopes Inc. (NASDAQ: ASPI), Noble Africa LLC (“Noble Africa”) , R.

ASP Isotopes Issues Letter to Shareholders

globenewswire.com · 4 Aug 2026

ASP Isotopes Issues Letter to Shareholders

DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) (“ASP Isotopes”, “ASPI” or the “Company”), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, today released the following letter to shareholders from its Executive Chairman and Chief Executive Officer, Paul Mann. Dear Fellow Shareholder, As we prepare to announce financial results for the second quarter of 2026, I wanted to take this opportunity to update you on the developments taking place at ASP Isotopes Inc. All of our business units are making considerable progress, group revenues are increasing, and three of our business units appear at an inflection point and are expected to make substantial contributions to achieving profitability in the near term: During 1H 2026, our global PET Labs group demonstrated organic revenue growth of over 50% as compared to 1H 2025.

Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company

businesswire.com · 17 Jul 2026

Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company

DALLAS & ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes" or “ASPI”), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, and ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or “NDRA”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that RedChip Companies will host an investor webi.

Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company

accessnewswire.com · 17 Jul 2026

Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company

Noble Africa was created to unlock the value of Renergen's Virginia Gas Project through a public company focused on helium and LNG Learn why the Virginia Gas Project is positioned to become one of the world's most strategic helium developments as global supply tightens and demand accelerates DALLAS, TX AND ANN ARBOR, MI / ACCESS Newswire / July 17, 2026 / ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes" or "ASPI"), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, and ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or "NDRA"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that RedChip Companies will host an investor webinar featuring Noble Africa, a wholly owned subsidiary of ASP Isotopes and the holding company for Renergen Limited, on Tuesday, July 21, 2026, at 4:15 p.m. ET. The webinar will highlight Noble Africa's proposed merger (the "Proposed Merger" and, together with the related transactions, the "Proposed Transactions") with ENDRA, which, if completed, is expected to result in Noble Africa becoming a Nasdaq-listed public company trading under the ticker symbol "NOBA.

Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders

globenewswire.com · 2 Jul 2026

Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

NDRA Stock Alert: Halper Sadeh LLC is Investigating Whether ENDRA Life Sciences Inc. is Obtaining a Fair Price for its Shareholders

gurufocus.com · 25 Jun 2026

NDRA Stock Alert: Halper Sadeh LLC is Investigating Whether ENDRA Life Sciences Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of ENDRA Life Sciences Inc. (NASDAQ: NDRA) with Noble Africa LLC. Upon closing of the

NDRA Stock Alert: Halper Sadeh LLC is Investigating Whether ENDRA Life Sciences Inc. is Obtaining a Fair Price for its Shareholders

businesswire.com · 25 Jun 2026

NDRA Stock Alert: Halper Sadeh LLC is Investigating Whether ENDRA Life Sciences Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of ENDRA Life Sciences Inc. (NASDAQ: NDRA) with Noble Africa LLC. Upon closing of the proposed transaction, ENDRA shareholders are expected to own approximately 3% of the combined company.Halper Sadeh encourages ENDRA shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalp.

ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing

gurufocus.com · 25 Jun 2026

ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing

ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes," “ASPI” or the "Company"), an advanced materials company focused on developing technologies and processes

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.